IQVIA Reports Strong Q3 2026 Results with Raised Full-Year Guidance
IQVIA Holdings Inc. (IQV) delivered robust third-quarter 2026 financial results, characterized by an 8% revenue increase to $4.428 billion and a significant acceleration in organic growth. The company saw strong performance across both its Clinical Research & Development and Commercial Solutions segments, bolstered by a massive surge in emerging biopharma funding, which rose over 85% year-over-year. Driven by high demand and operational efficiency, including the deployment of AI agents to improve win rates, IQVIA raised its full-year revenue, EBITDA, and adjusted EPS guidance. Despite headwinds from pass-through revenues affecting gross margins, the company reported a strong book-to-bill ratio of 1.2 and net new bookings in R&D solutions that reached a four-year high.
Topics: Adjusted EBITDA Contract Backlog Net New Bookings Revenue Growth